Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma.
Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma.
复制标题
DOI：
10.3390/cancers9070087
复制
发表时间：
2017-07-11
期刊：
影响因子：
5.2
通讯作者：
Abounader R
中科院分区：
文献类型：
--
作者：
Cruickshanks N;Zhang Y;Yuan F;Pahuski M;Gibert M;Abounader R
Glioblastoma (GBM) is a lethal brain tumor with dismal prognosis. Current therapeutic options, consisting of surgery, chemotherapy and radiation, have only served to marginally increase patient survival. Receptor tyrosine kinases (RTKs) are dysregulated in approximately 90% of GBM; attributed to this, research has focused on inhibiting RTKs as a novel and effective therapy for GBM. Overexpression of RTK mesenchymal epithelial transition (MET), and its ligand, hepatocyte growth factor (HGF), in GBM highlights a promising new therapeutic target. This review will discuss the role of MET in cell cycle regulation, cell proliferation, evasion of apoptosis, cell migration and invasion, angiogenesis and therapeutic resistance in GBM. It will also discuss the modes of deregulation of HGF/MET and their regulation by microRNAs. As the HGF/MET pathway is a vital regulator of multiple pro-survival pathways, efforts and strategies for its exploitation for GBM therapy are also described.
登录
查看更多内容
DOI：
10.1056/nejmoa1510016
发表时间：
2015-11-05
期刊：
The New England journal of medicine
影响因子：
--
作者：
Choueiri TK;Escudier B;Powles T;Mainwaring PN;Rini BI;Donskov F;Hammers H;Hutson TE;Lee JL;Peltola K;Roth BJ;Bjarnason GA;Géczi L;Keam B;Maroto P;Heng DY;Schmidinger M;Kantoff PW;Borgman-Hagey A;Hessel C;Scheffold C;Schwab GM;Tannir NM;Motzer RJ;METEOR Investigators
通讯作者：
METEOR Investigators
DOI：
10.4137/tog.s30534
发表时间：
2015
期刊：
Translational oncogenomics
影响因子：
--
作者：
Garajová I;Giovannetti E;Biasco G;Peters GJ
通讯作者：
Peters GJ
影响因子：
--
作者：
Cecchi F;Rabe DC;Bottaro DP
通讯作者：
Bottaro DP
影响因子：
4.7
作者：
Baldanzi G;Graziani A
通讯作者：
Graziani A
影响因子：
45.3
作者：
Chi, Andrew S.;Batchelor, Tracy T.;Iafrate, A. John
通讯作者：
Iafrate, A. John